Sonrotoclax, a powerful and specific BCL2 inhibitor for example, is currently being studied and appears to exhibit more significant reduction of tumor development and higher cytotoxic action in different hematologic cancer cells compared to VTC (86). The gene discussed is BCL2; the disease is neoplasm.